Literature DB >> 32645031

Modelling the effect of compliance with WHO salt recommendations on cardiovascular disease mortality and costs in Brazil.

Eduardo Augusto Fernandes Nilson1, Adriana Blanco Metlzer2, Marie-Eve Labonté3, Patrícia Constante Jaime1.   

Abstract

INTRODUCTION: Cardiovascular diseases (CVDs) represent the main cause of death among non-communicable diseases (NCDs) in Brazil, and they have a high economic impact on health systems. Most populations around the world, including Brazilians, consume excessive sodium, which increases blood pressure and the risk of CVDs.
OBJECTIVE: To model the estimated deaths and costs associated with CVDs, which are mediated by increased blood pressure attributable to excessive sodium consumption in adults from the perspective of the Brazilian public health system in 2017.
METHODS: We employed two macrosimulation methods, using top-down approaches and based on the same relative risks. The models estimated the mortality and costs-of-illness attributable to excessive sodium intake and mediated by hypertension for adults aged over 30 years in 2017. Direct healthcare cost data (inpatient care, outpatient care and medications) were extracted from the Ministry of Health information systems and official records.
RESULTS: In 2017, an estimated 46,651 deaths from CVDs could have been prevented if the average sodium consumption had been reduced to 2 g/day in Brazil. Premature deaths related to excessive sodium consumption caused 575,172 Years of Life Lost and US$ 752.7 million in productivity losses to the economy. In the same year, the National Health System's costs of hospitalizations, outpatient care and medication for hypertension attributable to excessive sodium consumption totaled US$192.1 million. The main causes of death and costs associated with CVDs were coronary heart disease and stroke, followed by hypertensive disease, heart failure and aortic aneurysm.
CONCLUSION: Excessive sodium consumption is estimated to account for 15% of deaths by CVDs and to 14% of the inpatient and outpatient costs associated with CVD. It also has high societal costs in terms of premature deaths. CVDs are a leading cause of disease and economic burden on the global, regional and country levels. As a largely preventable and treatable conditions, CVDs require the strengthening of cost-effective policies, supported by evidence, including modeling studies, to reduce the costs relating to illness borne by the Brazilian public health system and society.

Entities:  

Year:  2020        PMID: 32645031     DOI: 10.1371/journal.pone.0235514

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  10 in total

Review 1.  Modelling health and economic impact of nutrition interventions: a systematic review.

Authors:  Mariska Dötsch-Klerk; Maaike J Bruins; Patrick Detzel; Janne Martikainen; Reyhan Nergiz-Unal; Annet J C Roodenburg; Ayla Gulden Pekcan
Journal:  Eur J Clin Nutr       Date:  2022-10-04       Impact factor: 4.884

2.  Therapeutic Drug Monitoring of Anti-infective Drugs: Implementation Strategies for 3 Different Scenarios.

Authors:  Hannah Yejin Kim; Kenneth C Byashalira; Scott K Heysell; Anne-Grete Märtson; Stellah G Mpagama; Prakruti Rao; Marieke G G Sturkenboom; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

3.  Impact of salt intake reduction on CVD mortality in Costa Rica: A scenario modelling study.

Authors:  Jaritza Vega-Solano; Adriana Blanco-Metzler; Karol Madriz-Morales; Eduardo-Augusto Fernandes-Nilson; Marie Eve Labonté
Journal:  PLoS One       Date:  2021-01-12       Impact factor: 3.240

4.  Patients' Perspectives About the Treatment They Receive for Cardiovascular Diseases and Mental Disorders: Web-Based Survey Study.

Authors:  Philippe Courtet; Catherine Pecout; Anne-Félice Lainé-Pellet; Michael Chekroun; Charlotte Avril; Jean-Jacques Mourad
Journal:  JMIR Form Res       Date:  2022-03-16

5.  Reducing Sodium Consumption in Mexico: A Strategy to Decrease the Morbidity and Mortality of Cardiovascular Diseases.

Authors:  Ismael Campos-Nonato; Jorge Vargas Meza; Claudia Nieto; Ana Carolina Ariza; Simón Barquera
Journal:  Front Public Health       Date:  2022-03-22

6.  Projected impact of change in the percentage of energy from each NOVA group intake on cardiovascular disease mortality in Brazil: a modelling study.

Authors:  Patricia Vasconcelos Leitão Moreira; Adélia da Costa Pereira de Arruda Neta; Flávia Emília Leite de Lima Ferreira; Jevuks Matheus de Araújo; Maria Laura da Costa Louzada; Rafaela Lira Formiga Cavalcanti de Lima; Rodrigo Pinheiro de Toledo Vianna; José Moreira da Silva Neto; Zoe Colombet; Martin O'Flaherty
Journal:  BMJ Open       Date:  2022-04-26       Impact factor: 3.006

7.  Development and validation of an instrument to assess Brazilians' knowledge, perceptions, and behaviors toward salt and sodium.

Authors:  Alícia Tavares da Silva Gomes; Kamila Tiemann Gabe; Patricia Constante Jaime
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-04-07       Impact factor: 2.885

8.  Prevalence of Excess Sodium Intake and Their Corresponding Food Sources in Adults from the 2017-2018 Brazilian National Dietary Survey.

Authors:  Paula Victória Félix; Michelle Alessandra De Castro; Carlos Alberto Nogueira-de-Almeida; Mauro Fisberg
Journal:  Nutrients       Date:  2022-09-28       Impact factor: 6.706

9.  Dietary Salt Reduction, Prevalence of Hypertension and Avoidable Burden of Stroke in Vietnam: Modelling the Health and Economic Impacts.

Authors:  Leopold Ndemnge Aminde; Hai N Phung; Dung Phung; Linda J Cobiac; J Lennert Veerman
Journal:  Front Public Health       Date:  2021-06-04

10.  Dietary Sodium and Potassium Intake: Data from the Mexican National Health and Nutrition Survey 2016.

Authors:  Jorge Vargas-Meza; Manuel A Cervantes-Armenta; Ismael Campos-Nonato; Claudia Nieto; Joaquín Alejandro Marrón-Ponce; Simón Barquera; Mario Flores-Aldana; Sonia Rodríguez-Ramírez
Journal:  Nutrients       Date:  2022-01-11       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.